IBSA’s international expansion continues with interesting updates on the French side. At the end of July 2021, IBSA Institut Biochimique SA acquired 100% of the share capital of its historical distributor, Laboratoires Genevrier SAS, thus strengthening its footprint on the French market.
Laboratoires Genevrier was founded in 1920 in Neuilly-sur-Seine, near Paris and was later relaunched with a new momentum in 1987, becoming the IBSA Group’s French distributor. The company’s headquarters is at the heart of Sophia-Antipolis, Europe’s leading technology park located near Nice on the Cote d'Azur. Laboratoires Genevrier, whose name will change to IBSA Pharma SAS, offers a wide range of pharmaceutical products in several different therapeutic areas, such as: endocrinology, reproductive medicine, pain and inflammation, osteoarticular, dermatology, uro-gynaecology and consumer health. IBSA Pharma SAS will also soon launch its products in the aesthetic medicine.
“The acquisition of Laboratoires Genevrier reflects the Group's strategy aimed at strengthening its commercial structure through the opening of subsidiaries”, says Massimiliano Licenziati, President of IBSA Pharma SAS. “Today, with the opening of the new French subsidiary, IBSA consolidates its presence in the pharmaceutical sphere by becoming an unquestioned player.”
Fabrice Jover, General Manager at IBSA Pharma SAS, comments: “I am very happy to be part of IBSA Group and to share know-how and resources, which will allow us to expand our product portfolio to better meet the needs of the French market, thus further developing our business.”
